APTBIO of Shanghai Completes $28 Million Round for Proteomics Services
publication date: Apr 23, 2020
APTBIO, a Shanghai proteomic services company, completed a $28 million Series A financing, led by Luxin Venture Capital and Wuxi New District Investment Group. The company offers a broad portfolio of bio-analytical services to support drug discovery and preclinical development for biologics. APTBIO considers itself to be a pioneer in proteomics and metabolomics, Its proprietary platforms, based on mass spectrometry, offer biomarker discovery/validation services and innovative diagnostic tests. It provides proteomics, metabolomics and bioinformatics services to academic and commercial life science researchers. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.